Zelluna ASA to Publish Q3 2026 Results and Update on ZIMA-101 Study

Oslo, 13 October 2026, Zelluna ASA, a clinical-stage biotechnology company pioneering allogeneic, off-the-shelf T-cell receptor-based natural killer (TCR-NK) cell therapies for solid cancers, is set to publish its financial results for the third quarter of 2026 on Thursday, 5 November 2026. The company will also provide an update on its activities during the quarter, including progress in the ongoing Phase 1 ZIMA-101 study of ZI-MA4-1, its first-in-class MAGE-A4-targeting TCR-NK cell therapy for advanced solid tumours.

The presentation will be available via a live webcast on Zelluna’s website at 09:00 CET on Thursday, 5 November 2026. Participants will be able to submit questions during the presentation, and the webcast recording will remain available on the Company’s website after the event. The quarterly report and presentation materials will be published on the Company’s website at 07:00 CET on Thursday, 5 November 2026, ahead of the webcast.

Zelluna’s focus on developing innovative TCR-NK cell therapies for solid cancers continues to advance, with the ZIMA-101 study showing promising progress. The company’s commitment to bringing new treatments to patients suffering from advanced solid tumours is a significant step in the field of biotechnology.